General overview of lung transplantation and review of organ allocation.
General overview of lung transplantation and review of organ allocation.
复制标题
DOI：
10.1513/pats.200807-072go
复制
发表时间：
2009-01-15
期刊：
影响因子：
--
通讯作者：
Garrity, Edward R Jr
中科院分区：
文献类型：
--
作者：
Orens, Jonathan B;Garrity, Edward R Jr
肺移植是各种终末期肺部疾病患者的既定治疗选择。对于终末期肺部疾病患者，肺移植可以大大延长生命;然而，与其他实体器官移植相比，肺移植的生存统计数据仍然苍白。急性细胞排斥反应（ACR）是常见的肺移植后发生在高达90%的患者。慢性排斥反应，表现为闭塞性细支气管炎综合征（BOS），仍然是肺移植长期成功的“致命弱点”。不幸的是，BOS在肺移植后很常见，大多数患者在移植后5年发生。肺移植的候选人应该有接近终末期的肺部疾病，预期寿命有限。今天的器官分配是基于手术的需要和生存能力，并且很有可能改善生活质量。在这个迷人的领域的进展的细节包括在这个问题上的几篇文章。
Lung transplantation is an established treatment option for patients with a wide variety of end-stage lung diseases. For patients with end-stage lung disease, lung transplant can prolong life substantially; however, the survival statistics for lung transplants still pale compared with other solid organ transplants. Acute cellular rejection (ACR) is common after lung transplantation occurring in up to 90 percent of patients. Chronic allograft rejection, manifest as bronchiolitis obliterans syndrome (BOS), remains the "Achilles heel" to the long-term success of lung transplantation. Unfortunately, BOS is common after lung transplantation, occurring in a majority of patients by 5 years after transplant. Candidates for lung transplantation should have near-end-stage lung disease with a limited life expectancy. Allocation of organs today is based upon need and survivability of the operation, and there is a high likelihood of improvement in quality of life. Details of the advances in this fascinating field are included in the several articles in this issue.